ASCO GU 2020 Prostate Cancer

Viewing 1-20 of 92 articles

Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-233 (Ra-223) in men with bone metastatic castration-resistant prostate cancer - Poster

ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial

ASCO GU 2020: A Phase II Study of Talazoparib in Men with DNA Damage Repair Mutations and Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Assessment of Inherited DNA Repair Defects in African-American and Caucasian Men with Prostate Cancer

ASCO GU 2020: Phase Ib Study of Niraparib plus Androgen Receptor-Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Phase II Study of Cabazitaxel plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Safety and Effectiveness of Radium-223 Dichloride in Patients with mCRPC in Real-World Setting: A Japanese Post-Marketing Study

ASCO GU 2020: Treatment of Chemotherapy-Naïve mCRPC Using Abiraterone Acetate with or without Cabazitaxel

ASCO GU 2020: Preliminary Outcomes of A Prospective Observational Study of Combinatorial Abiraterone Acetate/Enzalutamide and Radical Radiotherapy in Nonmetastatic Node-Positive Prostate Cancer

ASCO GU 2020: Prognostic Factors that Affect Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

ASCO GU 2020: A Comparison of Sipuleucel-T Product Parameters from Two Phase III Studies: PROVENT in Active Surveillance Prostate Cancer and IMPACT in Metastatic Castrate-Resistant Prostate Cancer

ASCO GU 2020: The Association of Humoral Antigen Spread with Cytotoxic T Lymphocyte Activity after Sipuleucel-T Treatment in Two Phase II Clinical Studies: STAMP and STRIDE

ASCO GU 2020: Assessing Different Sequencing Regimens of Atezolizumab and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

ASCO GU 2020: Correlative Measures of Tumor Response in the Phase II GALAHAD Study

ASCO GU 2020: The Use of Novel Tools in the Active Surveillance

ASCO GU 2020: Overall Survival in Men with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Receiving Bicalutamide Followed by Enzalutamide or Abiraterone

ASCO GU 2020: Implementation of Novel Tools in the Active Surveillance Pathway

ASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease

ASCO GU 2020: Real-World Analysis of Prostate-Specific Antigen Outcomes Among Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide

ASCO GU 2020: Meet the Regulators: History of Metastasis-Free Survival and Drug Development in Nonmetastatic Castrate-Resistant Prostate Cancer

1
2
3
4
5